周四早盘，中国抗体-B（03681.HK）股价出现显著上涨，盘中大涨5.95%，引起市场广泛关注。
消息面上，中国抗体-B于7月22日宣布了一项重要的融资计划。公司与23名认购人签订了认购协议，拟以每股2.03港元的价格发行1.82亿股新股份。这一价格较公告前的收盘价折让约16.12%。此次股份发行预计将为公司净筹得约3.69亿港元资金。
公司表示，此次融资所得将主要用于SM03（一种治疗类风湿关节炎的潜在单抗药物）的临床试验等用途。这一举措显示了公司对其核心产品研发的持续投入，有望推动公司在免疫性疾病治疗领域的发展。投资者对这一融资计划反应积极，推动了股价的上涨。然而，投资者仍需密切关注新股发行对公司长期发展的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.